On October 24, mindbodygreen shared its story on a small Spanish trial of Euromed’s Pomanox pomegranate extract under the line “Firms Your Skin”. The trial missed its main goal. The page links twice to the outlet’s own $60 skin supplement. One verb carries the sale. “Firms” is present tense, unhedged, and its object is your skin. The authors wrote that the extract “did not significantly affect” their main measure, a dark spot’s pigment, and that elasticity gains were exploratory and “require powered studies for confirmation”. Nutrition Insight, a trade site, put the same paper as “may support skin hydration and elasticity, trial suggests”. The tell: a present-tense verb about your body, with no “may”, on a page that carries a Shop now button. The page holds the slide in its own code. Its address says “may-help-skin-bounce-back”, its browser tab says “Can Firm”, and the version built to be shared says “Firms”. That is the tense that slips: may becomes can becomes does, the further the words travel from the study. The drawback, that the main result “fell short”, waits in the closing takeaway. The results list even credits “pomegranate juice”, though the article’s third paragraph says the women took capsules. The headline rides the halo: one good quality stands for all of them. A placebo-controlled trial in a Nature journal lends its weight to a claim the trial calls exploratory, and the outlet’s wellness name lends its weight to the shop. The two “Shop now” links lead to best skin+, $60, sold by mindbodygreen, with blood orange, phytoceramides and astaxanthin and no pomegranate. Euromed, which makes Pomanox, supplied every capsule and placebo; none of the coverage names who paid for the trial.
